Qizhen Shi, MD., PhD
Investigator, Children's Research Institute; associate professor, Medical College of Wisconsin.
Hemophilia, the association between von Willebrand factor and factor FVIII, gene therapy, hematopoietic stem cells, immune response in gene therapy.
Medical degree, Fujian Medical University, China, 1990; MS, Hematology, Fujian Medical University, Fuzhou, Fujian, China, 1993; doctorate, Hematology, Fujian Medical University, Fuzhou, Fujian, China, 1998; resident in Internal Medicine, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fujian, China, 1995; postdoctoral fellow, Medical College of Wisconsin, Pediatric Oncology, 2001; Postdoctoral Fellow, Medical College of Wisconsin, Pediatric Hemtology Blood Research Institute, Milwaukee, Wisconsin, 2006.
Chinese Medical License (Registration no: 210020. China).
The Leader of Fujian Provincial Academic and Technology, 1998; Outstanding New Investigator Award, American Society of Gene and Cell Therapy, 2011; Symposium HOT Topic Presenter, the Scientific and Standardization Committee of International Society for Thrombosis and Haemostasis, 2012; Member, American Society of Hematology, International Society on Thrombosis and Haemostasis, American Heart Association - Scientific Council; Abstract reviewer for the 54th American Society of Hematology Annual Meeting, 2012; Ad Hoc Reviewer for Blood, Journal of Thrombosis and Haemostasis, Current Gene Therapy, Drug Design, Development and Therapy, Molecular Pharmaceutics, Journal of Genetic Syndromes & Gene Therapy; Ad Hoc Reviewer for the Natural Sciences and Engineering Research Council of Canada for Collaborative Health Research Projects and the Trust/DBT India Alliance Intermediate Fellowship for Biomedical Research Fellowship Program.
- Shi Q, Wilcox DA, Fahs SA, Weiler H, Well CC, Cooley BC, Desai D, Morateck PA, Gorski J and Montgomery RR. Factor VIII Ectopically Targeted to Platelets is Therapeutic in Hemophilia A with High-titer Inhibitory Antibodies. J Clin Invest. 2006, 116(7):1974-1982. [Article accompanied by invited editorial commentary. High K.A. the Leak Stops here: Platelets as Delivery Vehicles for coagulation Factors. J Clin Invest. 2006; 116(7):1840-1842.]
- Shi Q.*, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, Weiler H, Montgomery RR. Syngeneic Transplantation of Hematopoietic Stem Cells (HSC) that are Genetically Modified to Express Factor VIII (FVIII) in Platelets Restores Hemostasis to Hemophilia A Mice with Pre-Existing FVIII Immunity. Blood. 2008; 112 (7):2713-2721 (*Corresponding author). [Article accompanied by invited editorial commentary. Tuddenham E.G.D. Killing 2 Birds with 1 Stone. Blood. 2008; 112 (7):2595.]
- Shi Q*, Fahs SA, Kuether EL, Cooley BC, Weiler H, Montgomery RR. Targeting FVIII Expression to Endothelial Cells Regenerates a Releasable Pool of FVIII and Restores Hemostasis in a Mouse Model of Hemophilia A. Blood. 2010; 116(16): 3049-57 (*Corresponding author). [Article was highlighted by Vascular Biology Publications Alert 2010.]
- Kanaji S, Kuether EL, Schroeder JA, Fahs SA, Ware J, Montgomery RR, Shi Q. Lentivirus-mediated Gene Therapy of Bernard-Soulier Syndrome in a GPIb Deficient Mouse Model. Mol Ther. 2012; 20(3):625-32.
- Kuether EL, Fahs SA, Cooley BC, Schroeder JA, Chen Y, Montgomery RR, Wilcox DA, Shi Q. Lentivirus-mediated Platelet Gene Therapy of Murine Hemophilia A with Pre-existing Anti-FVIII Immunity. J Thromb Haemost. 2012; 10(8):1570-80. [Article was published In Focus and accompanied by invited editorial commentary. Chuah M and Vanderdriessche T. Platelet-directed Gene Therary Overcomes Inhibitory Antibodies to FVIII. J Thromb Haemost. 2012; 10(8):1566-1569].
- Shi Q, Kuether EL, Schroeder JA, Perry CI, Fahs SA, Gil JC, Montgomery RR. FVIII Inhibitors: VWF makes a Difference in Vitro and in Vivo. J Thromb Haemost. 2012 Aug 21. doi:10.1111/j.1538-7836.2012.04902.x. [Epub ahead of print]. (*Corresponding author). [Article published In Focus and accompanied by invited editorial commentary. Ragni MV. VWF:Factor VIII Protector and Friend. J Thromb Haemost. 2012 Sep 13. doi: 10.1111/j.1538-7836.2012.04922.x. [Epub ahead of print].
- Platelet-Derived FVIII Gene Therapy of Hemophilia A, National Institutes of Health/NHLBI RO1, principal investigator.
- Platelet Gene Therapy for Hemophilia, MACC Fund, principal investigator.
Medical College of Wisconsin
Blood Research Institute
8727 Watertown Plank Rd.
Wauwatosa, WI 53226
Phone: (414) 937-3853
Fax: (414) 937-6811
Investigator in the areas of: